Crinetics Pharmaceuticals (CRNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors for a three-year term expiring at the 2029 annual meeting.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation as disclosed in the proxy statement.
Proxyholders authorized to vote on other business arising at the meeting or any adjournments.
Board of directors and corporate governance
Nominees for director positions include Caren Deardorf, Weston Nichols, Ph.D., and Stephanie S. Okey, M.S.
Directors to serve three-year terms if elected.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the independent auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Crinetics Pharmaceuticals
- All proposals passed, including director elections and auditor ratification.CRNX
AGM 202618 Jun 2026 - Q3 net loss rose to $76.8M; $1.4B cash funds pipeline and 2025 launch plans.CRNX
Q3 20244 Jun 2026 - Q2 2024 saw strong cash reserves, positive clinical data, and NDA plans for paltusotine.CRNX
Q2 20244 Jun 2026 - $1.4B cash runway, NDA acceptance, and late-stage pipeline set stage for 2025 growth.CRNX
Q4 20244 Jun 2026 - Q1 2025 net loss widened, but $1.3B cash supports pipeline, launch, and global expansion.CRNX
Q1 20254 Jun 2026 - Net loss reached $115.6M in Q2 2025 as paltusotine neared FDA approval and cash reserves stayed strong.CRNX
Q2 20254 Jun 2026 - PALSONIFY's launch fueled Q1 revenue growth, global expansion, and robust liquidity despite higher losses.CRNX
Q1 202611 May 2026 - Annual meeting to elect directors, ratify PwC, and approve executive pay, with strong governance focus.CRNX
Proxy filing29 Apr 2026 - PALSONIFY launch drives strong early uptake, net loss widens, cash runway extends into 2029.CRNX
Q3 202516 Apr 2026